Imugene Secures A$46 Million for Clinical Trials

Imugene Limited (AU:IMU) has released an update.

Imugene Limited has secured a significant capital boost of up to A$46 million through the issuance of convertible notes and warrants to CVI Investments Inc. This funding is set to support the company’s clinical trials, including programs like azer-cel, onCARlytics, and VAXINIA, extending its cash runway to the end of 2025. The move positions Imugene to anticipate pivotal clinical data in the coming year, offering potential growth opportunities for investors.

For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.